A meta-analysis of 17 randomized trials reported lower pooled odds of postoperative delirium with remimazolam. Variation in procedures, drug regimens, and delirium assessment constrains a universal safety ranking.
The pooled result
Zhou and colleagues combined trials involving 3,133 adults. The pooled odds ratio was 0.71, with a 95% confidence interval of 0.52–0.97, for remimazolam compared with propofol. The search covered literature through March 29, 2025.
That estimate describes relative odds across included trials. It does not mean every patient’s probability of delirium falls by 29 percentage points. An absolute benefit depends on the underlying event rate and the applicable population.
Subgroups do not settle every difference
The authors examined age, blinding, follow-up, and diagnostic instruments. Although some subgroup estimates differed, the subgroup comparisons did not establish significant differences. A larger-looking estimate in one subgroup is not itself proof of a special benefit.
Doses, co-administered drugs, procedures, follow-up periods, and definitions varied. The synthesis used study-level rather than individual-patient data and did not remove every source of clinical heterogeneity.
Appropriate use
The review supports discussion of delirium as a measured comparative endpoint. It does not establish that remimazolam eliminates delirium, that all benzodiazepines share its result, or that the drug choice caused an individual postoperative cognitive event. Hypothesized mechanisms should remain distinct from the pooled clinical finding.
Source
Original analysis of the supplied paper: Remimazolam vs propofol for postoperative delirium in adults undergoing general anesthesia A meta an. Paper identifier: PMC12533823.
Leave a Reply